These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12413848)

  • 21. Biphenylsulfonamide endothelin receptor antagonists. Part 3: structure-activity relationship of 4'-heterocyclic biphenylsulfonamides.
    Murugesan N; Gu Z; Stein PD; Spergel S; Bisaha S; Liu EC; Zhang R; Webb ML; Moreland S; Barrish JC
    Bioorg Med Chem Lett; 2002 Feb; 12(4):517-20. PubMed ID: 11844662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and structure-activity relationships in a series of ethenesulfonamide derivatives, a novel class of endothelin receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tokunaga T; Tanaka A; Tsukamoto S; Yanagisawa I
    Chem Pharm Bull (Tokyo); 2001 Dec; 49(12):1593-603. PubMed ID: 11767080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF.
    Warner TD; Allcock GH; Corder R; Vane JR
    Br J Pharmacol; 1993 Oct; 110(2):777-82. PubMed ID: 8242251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
    Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
    J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ET
    Khadtare N; Stephani R; Korlipara V
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2281-2285. PubMed ID: 28462837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity.
    Boyd SA; Mantei RA; Tasker AS; Liu G; Sorensen BK; Henry KJ; von Geldern TW; Winn M; Wu-Wong JR; Chiou WJ; Dixon DB; Hutchins CW; Marsh KC; Nguyen B; Opgenorth TJ
    Bioorg Med Chem; 1999 Jun; 7(6):991-1002. PubMed ID: 10428367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists.
    Murugesan N; Gu Z; Stein PD; Spergel S; Mathur A; Leith L; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Morrison RA; Webb ML; Moreland S; Barrish JC
    J Med Chem; 2000 Aug; 43(16):3111-7. PubMed ID: 10956219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries.
    Liang F; Glascock CB; Schafer DL; Sandoval J; Cable L; Melvin L; Hartman JC; Pitts KR
    Can J Physiol Pharmacol; 2010 Aug; 88(8):840-9. PubMed ID: 20725142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bis-sulfonamides as endothelin receptor antagonists.
    Boss C; Bolli MH; Weller T; Fischli W; Clozel M
    Bioorg Med Chem Lett; 2003 Mar; 13(5):951-4. PubMed ID: 12617928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.
    Ksander GM; Shetty SS; DelGrande D; Balwierczak JL; Bruseo CW; Savage P; deJesus R; Yuan A; Webb RL; Jeng AY
    Can J Physiol Pharmacol; 2002 May; 80(5):464-9. PubMed ID: 12056554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of L-749,329, an ET(A)/ET(B) endothelin receptor antagonist, in a porcine coronary artery injury model of vascular restenosis.
    Huckle WR; Drag MD; Acker WR; Powers M; McFall RC; Holder DJ; Walsh TF; Schwartz RS; Greenlee WJ; Johnson RG
    Circulation; 2001 Apr; 103(14):1899-905. PubMed ID: 11294810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benzofuro[3,2-b]pyridines as mixed ET(A)/ET(B) and selective ET(B) endothelin receptor antagonists.
    Mederski WW; Osswald M; Dorsch D; Christadler M; Schmitges CJ; Wilm C
    Bioorg Med Chem Lett; 1999 Feb; 9(4):619-22. PubMed ID: 10098676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.
    Warner TD; Allcock GH; Vane JR
    Br J Pharmacol; 1994 May; 112(1):207-13. PubMed ID: 8032643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The endothelin A receptor antagonists PD 156707 (CI-1020) and PD 180988 (CI-1034) reverse the hypoxic pulmonary vasoconstriction in the perinatal lamb.
    Coe Y; Haleen SJ; Welch KM; Liu YA; Coceani F
    J Pharmacol Exp Ther; 2002 Aug; 302(2):672-80. PubMed ID: 12130731
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists.
    Jae HS; Winn M; von Geldern TW; Sorensen BK; Chiou WJ; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 2001 Nov; 44(23):3978-84. PubMed ID: 11689084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity.
    Fukami T; Yamakawa T; Niiyama K; Kojima H; Amano Y; Kanda F; Ozaki S; Fukuroda T; Ihara M; Yano M; Ishikawa K
    J Med Chem; 1996 Jun; 39(12):2313-30. PubMed ID: 8691426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformationally tailored N-[(2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)carbonyl]proline templates as molecular tools for the design of peptidomimetics. Design and synthesis of fibrinogen receptor antagonists.
    Stefanic P; Simoncic Z; Breznik M; Plavec J; Anderluh M; Addicks E; Giannis A; Kikelj D
    Org Biomol Chem; 2004 May; 2(10):1511-7. PubMed ID: 15136808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
    Willette RN; Sauermelch CF; Storer BL; Guiney S; Luengo JI; Xiang JN; Elliott JD; Ohlstein EH
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S149-57. PubMed ID: 9595425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig.
    Hemsén A; Modin A; Wanecek M; Malmström RE; Weitzberg E
    Eur J Pharmacol; 1996 Dec; 318(2-3):369-76. PubMed ID: 9016927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.
    van Muijlwijk-Koezen JE; Timmerman H; Vollinga RC; Frijtag von Drabbe Künzel J; de Groote M; Visser S; IJzerman AP
    J Med Chem; 2001 Mar; 44(5):749-62. PubMed ID: 11262085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.